PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
ORGANIZATION
EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
The Japanese government’s proposed cost-effectiveness assessment (CEA) scheme carries “arbitrary” product selection criteria with “too low” a peak sales threshold, which would force companies to shoulder unnecessary development costs to prepare data for an unduly broad scope of drugs, EFPIA…
To read the full story
Related Article
- EFPIA Official Prods Japan to Limit CEA Application to Financially Impactful Drugs
March 19, 2019
- Tough CEA Rules for Cost-Based Method Products Targeting Imports: EFPIA Japan Vice Chair
February 7, 2019
- PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework
February 5, 2019
- Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
ORGANIZATION
- FPMAJ Urges Member Groups to Share Government PHP Security Alert
October 26, 2026
- JPWA Reports No Damage from PHP Vulnerability, Renews “No” to FY2027 Revision
October 23, 2026
- Ex-JMA Vice President, Lawmaker Hanyuda Remembered at Memorial Service
October 21, 2026
- Japan Generics Society Calls for Risk-Based Nitrosamine Controls
October 16, 2026
- Japan Expert Calls for Earlier Access to Anti-Obesity Drugs
October 16, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…